reminyl 12mg film-coated tablets
janssen-cilag international nv turnhoutsewes 30, b-2340 beerse, belgium - galantamine - film-coated tablet - galantamine - psychoanaleptics
xapimant 10mg film-coated tablet
sandoz philippines corporation - memantine hydrochloride - film-coated tablet - 10mg
none 10 mg film-coated tablet
sandoz philippines corporation; distributor: ritemed phils., inc. - memantine hydrochloride - film-coated tablet - 10 mg
memantine sandoz 10 mg film-coat. tabl.
sandoz sa-nv - memantine hydrochloride 10 mg - eq. memantine 8,31 mg - film-coated tablet - memantine
memantine sandoz 10 mg film-coat. tabl.
sandoz sa-nv - memantine hydrochloride 10 mg - eq. memantine 8,31 mg - film-coated tablet - memantine
memantine sandoz 20 mg film-coat. tabl.
sandoz sa-nv - memantine hydrochloride 20 mg - eq. memantine 16,62 mg - film-coated tablet - memantine
memantine sandoz 20 mg film-coat. tabl.
sandoz sa-nv - memantine hydrochloride 20 mg - eq. memantine 16,62 mg - film-coated tablet - memantine
memantine hydrochloride tablet, film coated
aurobindo pharma limited - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 5 mg - memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the alzheimer’s type. memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of memantine hydrochloride in pregnant women. adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. these doses are higher than those used in humans at the maximum recommended daily dose of memantine hydrochloride [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population
memantine hydrochloride tablet, film coated
upsher-smith laboratories, llc - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 5 mg - memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the alzheimer's type. memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of memantine in pregnant women. adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. these doses are higher than those used in humans at the maximum recommended daily dose of memantine [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal d
memantine hydrochloride tablet, film coated
unichem pharmaceuticals (usa), inc. - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 5 mg - memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the alzheimer's type. memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of memantine hydrochloride in pregnant women. adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine hydrochloride during pregnancy at doses associated with minimal maternal toxicity. these doses are higher than those used in humans at the maximum recommended daily dose of memantine hydrochloride [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated po